Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRIMedical - Devices
+$0.84 today
- Market cap
- $1.35B
- Beta
- 2.18
- P/E (TTM)
- -34.3
- EPS (TTM)
- -$0.28
Volume 0.26M
Average 0.92M
LMRI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Lumexa Imaging Holdings, Inc. Common StockNASDAQ: LMRI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA of $33.45M in Q1 FY2026
Q1 FY2026 EBITDA was $33.45M.
Context
- EBITDA amounted to 13.9% of revenue in FY2025, up 1.8 pp from a year earlier.
- EBITDA increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $260.91M (+84.1%) for the fiscal year ending Dec 2026, a step up from the +24.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $33.45M+120.7% QoQ
- Last fiscal yearDec 2025
- $141.71M+24.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +24.3% | +84.1% | +59.8 pp |
| 3-year CAGR | — | +24.1% | — |
| 5-year CAGR | +16.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 141.71M USD
- Year-over-year change
- +24.3%
- 2-year CAGR
- +22.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 141.71M | +24.3% |
| FY2024 | 2024-12-31 | 114M | +20.5% |
| FY2023 | 2023-12-31 | 94.58M | — |
EBITDA vs competitors
How LMRI compares with its peers on the latest reported figures
- LMRI's FY2025 EBITDA of $141.71M is the lowest of the 2 companies compared; the peer median is $295.2M.
- Its year-over-year change of +24.3% is the highest of 2, against a peer median of -1.7%.
- EBITDA amounts to 13.9% of revenue for LMRI, versus a peer median of 12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $295.2M | -1.7% | -3.0% | 12.4% | |
LMRILumexa Imaging Holdings, Inc. Common Stock | FY2025 | $141.71M | +24.3% | — | 13.9% |
| Peer median (excluding LMRI) | $295.2M | -1.7% | -3.0% | 12.4% | |
Competitors are the stored peer set for LMRI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 935.93M | 948.87M | 1.02B |
| Cost of Revenue | 836.96M | 852.61M | 905.9M |
| Gross Profit | 98.97M | 96.26M | 117.19M |
| Gross Margin | 10.6% | 10.1% | 11.5% |
| Research & Development | 0 | 0 | 0 |
| Selling, General & Admin | 55.17M | 70.36M | 90.45M |
| Operating Expenses | 76.52M | 41.02M | 90.45M |
| Depreciation & Amortization | 72.14M | 57.16M | 55.39M |
| EBITDA | 94.58M | 114M | 141.71M |
| EBITDA Margin | 10.1% | 12.0% | 13.9% |
| Operating Income | 22.45M | 55.24M | 26.73M |
| Operating Margin | 2.4% | 5.8% | 2.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 141.69M | 136.03M | 118.54M |
| Other Income / Expenses | (141.69M) | (134.44M) | (58.95M) |
| Income Before Tax | (119.25M) | (79.19M) | (32.22M) |
| Pre-Tax Margin | -12.7% | -8.3% | -3.1% |
| Income Tax Expense | 2.98M | 14.91M | 14.89M |
| Net Income | (122.23M) | (94.1M) | (47.1M) |
| Net Margin | -13.1% | -9.9% | -4.6% |
| EPS (Basic) | (1.29) | (1.00) | (0.66) |
| EPS (Diluted) | (1.29) | (1.00) | (0.66) |
| Weighted Avg Shares | 94.57M | 94.57M | 70.98M |
| Weighted Avg Shares (Diluted) | 94.57M | 94.57M | 70.98M |
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
Intrinsic Alpha fair value
Locked
Current Price
$14.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.